BioCurity Pharmaceuticals Inc. offering is now closed and is no longer accepting investments.
INVEST IN BIOCURITY PHARMACEUTICALS INC. TODAY!
Because we believe that fighting cancer is hard enough!
$390,048 Raised
REASONS TO INVEST
Our technology may provide cost effective protection for millions of cancer patients every year from burns and other more serious side effects for cancer patients undergoing radiation therapy
Seven issued US patents with fully paid license for its technology in the US with a growing portfolio of international patents for our technology when patients are undergoing radiation plus chemotherapy
Our team of experts brings over two decades of cancer treatment research, global biotechnology distribution and corporate governance
ABOUT
HEADQUARTERS
110 Front Street, Suite 300
Jupiter, FL 33477
WEBSITE
View Site
BioCurity is a clinical stage biopharmaceutical company. We are developing our first drug to prevent or mitigate burns to the skin of patients with cancer during radiation therapy. The proposed drugs generated from BioCurity’s proprietary technology have been preclinically tested for multiple cancers including breast, lung, head and neck, prostate and colorectal cancer. The method of administration of the proposed drug includes a topical for the skin to prevent or mitigate skin damage (radiation dermatitis) and an intravenous (IV) formulation for internal tissue protection from radiation damage. We intend to accomplish these goals without impairing the effectiveness of radiation treatment or causing toxic side effects to the cancer patient. We believe our technology can save billions of dollars annually of healthcare dollars used now to treat preventable side effects of radiation therapy.
TEAM
Dr. Cheryl Baker
Chief Scientific Research Officer, and Director
Sam Merchant
Chairman of the Board of Directors
Nancy Cass, Esq
Director
TERMS
BioCurity Pharmaceuticals Inc.
Overview
PRICE PER SHARE
$4.25
DEADLINE
Jun 30, 2020
VALUATION
$34.02M
AMOUNT RAISED
$390,048
Breakdown
MIN INVESTMENT
$510
MAX INVESTMENT
$106,998
MIN NUMBER OF SHARES OFFERED
2,352
OFFERING TYPE
Equity
ASSET TYPE
PREFERRED
SHARES OFFERED
CF Convertible Preferred Stock
MAX NUMBER OF SHARES OFFERED
141,176
Maximum Number of Shares Offered subject to adjustment for bonus shares
Company | : | BioCurity Pharmaceuticals Inc. |
Corporate Address | : | 110 Front Street, Suite 300, Jupiter, FL 33477 |
Offering Minimum | : | $9,996.00 |
Offering Maximum | : | $599,998.00 |
Minimum Investment Amount(per investor) | : | $510.00 |
Terms
Offering Type | : | Equity |
Security Name | : | CF Convertible Preferred Stock |
Minimum Number of Shares Offered | : | 2,352 |
Maximum Number of Shares Offered | : | 141,176 |
Price per Share | : | $4.25 |
Pre-Money Valuation | : | $34,019,537.00 |
*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below
The 10% Bonus for StartEngine Shareholders
BioCurity Pharmaceuticals Inc. will offer 10% additional bonus shares for all investments that are committed by StartEngine Crowdfunding Inc. shareholders who invested over $1,000 or made at least two investments in StartEngine's own offerings.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of CF Convertible Preferred Stock at $4.25 / share, you will receive 110 CF Convertible Preferred Stock shares, meaning you'll own 110 shares for $425. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are cancelled or fail.
Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.
Irregular Use of Proceeds
The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Salary payments made to one’s self, a friend or relative. Vendor payments. Any expense labeled “Travel and Entertainment”.
ALL UPDATES
06.13.20
Notice of Funds Disbursement
[The following is an automated notice from the StartEngine team].
Hello!
As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.
This campaign will continue to accept investments until its indicated closing date.
Thanks for funding the future.
-StartEngine
05.19.20
BioCurity speaks with Dr. Clarence Brown, MD, about the lack of BioCurity's proprietary technology in the current environment, for cancer patients receiving radiation therapy
05.15.20
BioCurity receives a ‘Decision to Grant a Patent’ from the Japanese Patent Office (JPO) for their Proprietary Cerium Oxide Nanoparticle Radioprotectant
05.07.20
Notice of Funds Disbursement
[The following is an automated notice from the StartEngine team].
Hello!
As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.
This campaign will continue to accept investments until its indicated closing date.
Thanks for funding the future.
-StartEngine
04.28.20
Notice of Material Change in Offering
[The following is an automated notice from the StartEngine team].
Hello! Recently, a change was made to the BioCurity Pharmaceuticals Inc. offering. Here's an excerpt describing the specifics of the change:
BioCurity Pharmaceuticals Inc. has extended their campaign and updated 2019 financials.
When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.
04.16.20
Notice of Funds Disbursement
[The following is an automated notice from the StartEngine team].
Hello!
As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.
This campaign will continue to accept investments until its indicated closing date.
Thanks for funding the future.
-StartEngine
04.01.20
Notice of Funds Disbursement
[The following is an automated notice from the StartEngine team].
Hello!
As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.
This campaign will continue to accept investments until its indicated closing date.
Thanks for funding the future.
-StartEngine
03.25.20
Is BioCurity's science truly "game-changing"? Just ask this Oncologist..
03.13.20
Notice of Material Change in Offering
[The following is an automated notice from the StartEngine team].
Hello! Recently, a change was made to the BioCurity Pharmaceuticals Inc. offering. Here's an excerpt describing the specifics of the change:
BioCurity has extended their campaign.
When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.
03.04.20
Notice of Funds Disbursement
[The following is an automated notice from the StartEngine team].
Hello!
As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.
This campaign will continue to accept investments until its indicated closing date.
Thanks for funding the future.
-StartEngine
REWARDS
$1,003
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
JOIN THE DISCUSSION
0/2500
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
